RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of CTMX
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Red day on Thursday for CytomX Therapeutics
(Updated on Mar 28, 2024)

Buy or Hold candidate since Feb 26, 2024 Gain 32.12% PDF

The CytomX Therapeutics stock price fell by -0.457% on the last day (Thursday, 28th Mar 2024) from $2.19 to $2.18. During the last trading day the stock fluctuated 5.99% from a day low at $2.17 to a day high of $2.30. The price has been going up and down for this period, and there has been a 5.83% gain for the last 2 weeks. Volume has increased on the last day by 2 million shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 3 million shares were bought and sold for approximately $6.22 million.

The stock lies in the middle of a very wide and strong rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 43.35% during the next 3 months and, with a 90% probability hold a price between $2.63 and $4.31 at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

CTMX Signals & Forecast

There are mixed signals in the stock today. A sell signal was issued from a pivot top point on Monday, March 04, 2024, and so far it has fallen -20.44%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume rose on falling prices yesterday. This may be an early warning and the stock should be followed more closely. The CytomX Therapeutics stock holds buy signals from both short and long-term Moving Averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. On corrections down, there will be some support from the lines at $2.18 and $2.04. A breakdown below any of these levels will issue sell signals.

Support, Risk & Stop-loss for CytomX Therapeutics stock

CytomX Therapeutics finds support from accumulated volume at $2.15 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock may move much during the day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $0.130 between high and low, or 5.99%. For the last week, the stock has had daily average volatility of 5.68%.

Our recommended stop-loss: $2.09 (-4.12%) (This stock has high daily movements and this gives high risk. There is a sell signal from a pivot top found 18 days ago.)

Trading Expectations (CTMX) For The Upcoming Trading Day Of Monday 1st

For the upcoming trading day on Monday, 1st we expect CytomX Therapeutics to open at $2.22, and during the day (based on 14 day Average True Range), to move between $2.01 and $2.35, which gives a possible trading interval of +/-$0.174 (+/-7.97%) up or down from last closing price. If CytomX Therapeutics takes out the full calculated possible swing range there will be an estimated 15.95% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at $2.15 (1.38%) than the resistance at $2.25 (3.21%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Is CytomX Therapeutics stock A Buy?

Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for CytomX Therapeutics stock to perform well in the short-term.

Current score: 1.359 Buy Candidate Unchanged

Predicted Opening Price for CytomX Therapeutics of Monday, April 1, 2024

Fair opening price April 1, 2024 Current price
$2.22 ( 1.68%) $2.18

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for CTMX

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 2.35 7.65 %
R2 2.30 5.37 %
R1 2.27 3.96 %
Current price: 2.18
Support S1 2.17 -0.596 %
S2 2.14 -2.00 %
S3 2.09 -4.28 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 2.65 21.56 %
R2 2.54 16.51 %
R1 2.25 3.21 %
Current price 2.18
Support S1 2.15 -1.38%
S2 2.06 -5.50%
S3 1.69 -22.48%

FAQ

What is the symbol for CytomX Therapeutics Stock and on which exchange is it traded?
The symbol for CytomX Therapeutics is CTMX and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell CytomX Therapeutics Stock?
Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for CytomX Therapeutics stock to perform well in the short-term.

How to buy CytomX Therapeutics Stock?
CytomX Therapeutics Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy CytomX Therapeutics Stock.

What's the current price of CytomX Therapeutics Stock?
As of the end of day on the 2024-03-28, the price of an CytomX Therapeutics (CTMX) share was $2.18.

What is the 52-week high and low for CytomX Therapeutics Stock?
The 52-week high for CytomX Therapeutics Stock is $2.86 and the 52-week low is $1.04.

What is the market capitalization of CytomX Therapeutics Stock?
As of the 2024-03-28, the market capitalization of CytomX Therapeutics is 147.633M.

When is the next earnings date for CytomX Therapeutics?
The upcoming earnings date for CytomX Therapeutics is May 14, 2024.
Click to get the best stock tips daily for free!

About CytomX Therapeutics

CytomX Therapeutics CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatme... CTMX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT